美罗培南
加药
医学
感染性休克
治疗药物监测
病危
药代动力学
重症监护医学
药理学
败血症
内科学
抗生素
生物
微生物学
抗生素耐药性
作者
Ute Chiriac,Daniel Richter,Otto Roman Frey,Anka C. Röhr,Sophia Helbig,Stefan Hagel,Uwe Liebchen,Markus Alexander Weigand,Alexander Brinkmann
出处
期刊:Antibiotics
[Multidisciplinary Digital Publishing Institute]
日期:2023-06-27
卷期号:12 (7): 1112-1112
被引量:19
标识
DOI:10.3390/antibiotics12071112
摘要
Various studies have reported insufficient beta-lactam concentrations in critically ill patients. The optimal dosing strategy for beta-lactams in critically ill patients, particularly in septic patients, is an ongoing matter of discussion. This retrospective study aimed to evaluate the success of software-guided empiric meropenem dosing (CADDy, Calculator to Approximate Drug-Dosing in Dialysis) with subsequent routine meropenem measurements and expert clinical pharmacological interpretations. Adequate therapeutic drug exposure was defined as concentrations of 8–16 mg/L, whereas concentrations of 16–24 mg/L were defined as moderately high and concentrations >24 mg/L as potentially harmful. A total of 91 patients received meropenem as a continuous infusion (229 serum concentrations), of whom 60% achieved 8–16 mg/L, 23% achieved 16–24 mg/L, and 10% achieved unnecessarily high and potentially harmful meropenem concentrations >24 mg/L in the first 48 h using the dosing software. No patient showed concentrations <2 mg/L using the dosing software in the first 48 h. With a subsequent TDM-guided dose adjustment, therapeutic drug exposure was significantly (p ≤ 0.05) enhanced to 70%. No patient had meropenem concentrations >24 mg/L with TDM-guided dose adjustments. The combined use of dosing software and consecutive TDM promised a high rate of adequate therapeutic drug exposures of meropenem in patients with sepsis and septic shock.
科研通智能强力驱动
Strongly Powered by AbleSci AI